Cempra Authorized to Receive Funds From BARDA for a Phase 2/3 Clinical Trial of Solithromycin in Pediatric Patients
March 07, 2016 07:00 ET
|
Melinta Therapeutics, Inc.
Phase 2/3 Pivotal Trial Will Test Intravenous, Oral Capsule and Oral Suspension Formulations of Solithromycin in Pediatric Patients From Age 2 Months to 17 Years Cempra to Receive $25.5...
Cempra Reports Fourth Quarter and Full Year 2015 Financial Results and Provides Corporate Update
February 24, 2016 16:05 ET
|
Melinta Therapeutics, Inc.
CHAPEL HILL, N.C., Feb. 24, 2016 (GLOBE NEWSWIRE) -- Cempra, Inc. (Nasdaq:CEMP), a clinical-stage pharmaceutical company focused on developing antibiotics in the face of rising antibiotic resistant...
The Lancet Infectious Diseases Publishes Positive Phase 3 Study Results for Cempra’s Oral Solithromycin in Community-Acquired Bacterial Pneumonia
February 05, 2016 07:00 ET
|
Melinta Therapeutics, Inc.
Solithromycin met primary and secondary objectives of non-inferiority compared to moxifloxacin, a potent fluoroquinolone Cempra plans to complete a New Drug Application (NDA) submission to the FDA...
Cempra to Present at the Leerink Partners 5th Annual Global Healthcare Conference
February 03, 2016 07:30 ET
|
Melinta Therapeutics, Inc.
CHAPEL HILL, N.C., Feb. 03, 2016 (GLOBE NEWSWIRE) -- Cempra, Inc. (Nasdaq:CEMP), a clinical-stage pharmaceutical company focused on developing antibiotics to meet critical medical needs in the...
Cempra and Macrolide Pharmaceuticals Enter Synthetic Manufacturing Process Development Agreement for Solithromycin
February 01, 2016 07:30 ET
|
Melinta Therapeutics, Inc.
CHAPEL HILL, N.C. and WATERTOWN, Mass., Feb. 01, 2016 (GLOBE NEWSWIRE) -- Cempra, Inc. (NASDAQ:CEMP), a clinical-stage pharmaceutical company focused on developing antibiotics to meet critical...
Cempra to Ring NASDAQ Closing Bell to Mark 10th Anniversary
January 26, 2016 08:00 ET
|
Melinta Therapeutics, Inc.
CHAPEL HILL, N.C., Jan. 26, 2016 (GLOBE NEWSWIRE) -- Cempra, Inc. (Nasdaq:CEMP), a clinical-stage pharmaceutical company focused on developing antibiotics to meet critical medical needs in the...
Cempra Completes Public Offering of Common Stock
January 12, 2016 16:05 ET
|
Melinta Therapeutics, Inc.
CHAPEL HILL, N.C., Jan. 12, 2016 (GLOBE NEWSWIRE) -- Cempra, Inc. (Nasdaq:CEMP), a clinical-stage pharmaceutical company focused on developing antibiotics to meet critical medical needs in the...
Cempra Prices Public Offering of Common Stock
January 06, 2016 20:42 ET
|
Melinta Therapeutics, Inc.
CHAPEL HILL, N.C., Jan. 06, 2016 (GLOBE NEWSWIRE) -- Cempra, Inc. (Nasdaq:CEMP), a clinical-stage pharmaceutical company focused on developing antibiotics to meet critical medical needs in the...
Melinta Therapeutics Initiates Phase 3 Study of Baxdela in Hospital-Treated Community-Acquired Bacterial Pneumonia
January 06, 2016 08:00 ET
|
Melinta Therapeutics
New Haven, CT, Jan. 06, 2016 (GLOBE NEWSWIRE) -- Melinta Therapeutics, a privately held company developing novel antibiotics to treat bacterial infections, announced the initiation of an...
Cempra to Present at J.P. Morgan Healthcare Conference
January 06, 2016 07:30 ET
|
Melinta Therapeutics, Inc.
CHAPEL HILL, N.C., Jan. 06, 2016 (GLOBE NEWSWIRE) -- Cempra, Inc. (Nasdaq:CEMP), a clinical-stage pharmaceutical company focused on developing antibiotics to meet critical medical needs in the...